Friday and Saturday 16/17 Jumada al-Awwal 1447 AH 7/8 November 2025 AD
Bird influenza, which appeared three decades ago and is still mutating to reveal strains of it, has killed large numbers of wild and domestic birds around the world and led to human infections, which is worrying scientists about reducing its health, economic and environmental impacts. Today, a team of scientists led by Mathilde Rochard of the Erasmus University Medical Center in the Netherlands has developed a new experimental vaccine that provides comprehensive protection against all strains of highly pathogenic avian influenza (A5), including future strains that have not yet appeared.
The vaccine is characterized by the possibility of administering only one dose, which strengthens human defenses against the risk of a future pandemic. It relies on the design of a central HA protein that represents the common characteristics of all strains of the virus, and stimulates the immune system to produce effective antibodies against a wide range of viruses.
Despite the encouraging results, the vaccine is still in the study stage, and requires clinical trials on humans to verify its safety and effectiveness.
